Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2021-11-12 Director's Dealing
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details share transactions (purchases) by an executive (Jong Hwa Bhak) of Clinomics. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) as it reports personal share transactions by company directors and executives.
2021-11-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (purchases) made by an executive (Jong Hwa Bhak) of Clinomics. This is a standard regulatory filing for insider trading/director dealings in the South Korean market, which corresponds to the 'Director's Dealing' category.
2021-11-12 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for Clinomics Inc., covering the period from January 1, 2021, to September 30, 2021. It contains detailed corporate information, financial data, capital structure, and management details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-11 Korean
기타경영사항(특허권취득)(자율공시)(일부 오믹스 정보를 활용하여 전체 오믹스 정보로 확대 생산하는 장치 및 방법)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from Clinomics regarding the acquisition of a patent. It follows the standard format for a 'voluntary disclosure' (자율공시) in the Korean market, detailing the patent name, content, and utilization plan. Since it is a specific regulatory announcement regarding corporate operations that does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2021-11-01 Korean
기타경영사항(특허권취득)(자율공시)(질병 카테코리에 대한 통합 위험도 계산 및 시각화 장치 및 방법)
Regulatory Filings Classification · 1% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by Clinomics. It details the patent name, content, and utilization plan. Since it is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, governance, or shareholder-specific categories, it falls under the general regulatory filing category.
2021-10-26 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details the acquisition of shares by Renaissance Asset Management in Clinomics. This type of filing is specifically designed to notify the market and regulators of significant changes in share ownership, which falls under the 'Major Shareholding Notification' category.
2021-10-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.